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Abstract 
Prescription drug use is rising among Americans in all age groups.  In general, utilization of prescription 
medications increases with age due to chronic health conditions that require pharmaceutical interventions.  Because 
Medicaid is the single largest payer of prescription medications in Florida, this study’s objectives were to:  (1) 
examine Medicaid spending on recalled drugs for the 2001-02 fiscal year, (2) assess Medicaid expenditures for 
comparison drugs on the Medicaid preferred drug list for the same time period, and (3) contrast the drugs that 
received fast track approval with those undergoing standard approval.  In this study, Medicaid spending for 
recalled drugs was much lower than comparison drugs on the preferred drug list, in part because of a fewer number 
of claims and associated dispensing fees.  On the other hand, a higher percentage of recalled drugs had received 
fast track review than comparison drugs which were more likely to utilize the standard approval process.  Given the 
widespread use of prescription drugs, it is essential to assure the efficacy and safety of new medications prior to 
consumption by the general public, particularly because of their higher cost and impact on health expenditures.   
Florida Public Health Review, 2005; 2: 108-114 
 
Introduction 
In 2002, national drug expenditures totaled 
over $160 billion, a four-fold increase compared to 
approximately $40 billion a decade earlier (Centers 
for Medicare and Medicaid Services, 2004).  The 
escalation in prescription drug expenditures and 
consumption is due to a number of factors including:  
(1) greater availability — more rapid approvals of 
new drugs that replace existing lower cost drugs, (2) 
promotion of utilization — marketing to doctors and 
direct advertising to consumers, (3) payment 
mechanisms — growth of third party insurance 
coverage by private and public payers, and (4) 
clinical guidelines — recommending use of 
medications for treatment of chronic conditions 
(Bernt, 2001; General Accounting Office, 2004 
October).  Ten percent of U.S. health expenditures go 
toward prescription medications and prescription 
drug spending is rising faster than any other health 
care category (Centers for Medicare and Medicaid 
Services, 2004). 
  
Ensuring Consumer Drug Safety 
 According to the Centers for Disease 
Control and Prevention (CDC), approximately 45% 
of Americans take at least one prescription drug and 
one in six take at least three (CDC, 2004).   Given the 
widespread use of prescription drugs, it is essential to 
assure the efficacy and safety of medications prior to 
consumption by the general public.  As a 
consequence, the standard drug approval process 
conducted by the Food and Drug Administration 
(FDA) may take anywhere from 20 months to 15 
years and involve multiple stages (Meadows, 2002). 
In the first step, Stage 1, an investigational 
new drug (IND) application is submitted to the FDA.  
The manufacturer presents pre-clinical study data 
obtained from laboratory and animal tests.  Next, in 
Stage 2, clinical trials observe the new drug’s effects 
on the human body, including side effects and 
metabolic reactions.  Finally, in Stage 3, submission 
of a new drug application (NDA) requests the FDA to 
consider approving a new drug for marketing and 
distribution.  The NDA contains data collected from 
the clinical trials.  In reviewing the NDA, scientists 
evaluate the efficacy and safety of the potential drug, 
as well as its risk/benefit ratio to determine approval 
or disapproval.  After the drug has been approved for 
general public consumption, post-market studies 
continue to assess long-term effects and explore new 
therapeutic uses. 
 
Drug Safety Recalls and Withdrawals 
Post-market studies analyze the information 
collected from a larger and more diverse patient 
population than pre-approval clinical trials.  If a 
product has proven to be unsafe or ineffective at the 
prescribed dosages, it may be necessary for the FDA 
to initiate recall and/or withdrawal of the drug in 
question.  A recall, as defined by the FDA, involves 
actions to remove a product from the market (FDA, 
2002).  Recalls may be initiated by the drug 
manufacturer, by FDA request, or by FDA mandate.  
Removing a product from the market may be 
permanent or temporary such that it may be returned 
to market once the problem has been corrected.   
Some drugs may receive an alert if 
unexpected severe reactions are observed with use by 
the general public after market release.  On the other 
hand, the FDA recommends a drug for recall or 
market withdrawal if the risks of side effects and 
interactions significantly outweigh the drug’s 
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benefits.  The FDA classifies pharmaceutical product 
recalls into the three general categories below (FDA, 
2004).   
• Class I.  Recalls in this class involve dangerous 
or defective products that may cause serious 
health conditions or death with continued use or 
exposure.   
• Class II.  The FDA uses this type of recall to 
designate products that might cause temporary 
health problems or have a remote possibility of 
serious health consequences.   
• Class III.  These recalls relate to drugs that are 
unlikely to cause adverse health effects, but that 
have labeling or manufacturing (e.g., packaging) 
violations.  
Some analysts attribute the recent safety 
recalls to an act passed by Congress in 1992 that 
allowed pharmaceutical industry-paid user fees to 
finance expedited FDA reviews and approvals of new 
drugs (Carpenter et al., 2003).  Most drugs approved 
by the FDA use standard approval mechanisms or an 
expedited review that reduces the time frame prior to 
marketing and release to consumers.  Expedited 
reviews through fast track (i.e., accelerated approval) 
initiatives generally apply to drugs aimed at serious, 
life-threatening conditions or address unmet medical 
needs. 
   
Florida Analysis 
 Prescription drug use is rising among all 
Americans and use increases with age due to chronic 
health conditions that require pharmaceutical 
medications for treatment (CDC, 2004).  The sizeable 
segment of Florida’s population over age 65 
contributes to the state’s high demand and 
consumption of pharmaceutical products.  In 2003, 
Florida ranked fourth in the nation in retail 
prescription drug sales with a total of $10.57 billion 
spent, a 9.9% increase over the previous year (Kaiser 
Family Foundation, 2005).    
Moreover, prescription drug coverage is one 
of the benefits for Florida’s Medicaid recipients and 
Medicaid is the single largest payer for prescription 
medications in the state (Agency for Health Care 
Administration, 2004).  In the 2001-02 fiscal year, 
Florida spent a total of $1.65 billion for prescription 
drug coverage among Medicaid participants 
representing 10% of all prescriptions in the state 
(Agency for Health Care Administration, 2002).  The 
federal government passed Medicare reform 
legislation in 2003 that established prescription drug 
coverage for seniors starting January 1, 2006 
(Centers for Medicare and Medicaid Services, 2003). 
   
Methods 
The study’s objective was to investigate 
Medicaid spending on recalled drugs for fiscal year 
2001-02.  Medicaid expenditures for the comparison 
drugs on the Medicaid preferred drug list for the 
same time period also were examined.  Another 
component of the study contrasted the drugs that 
received fast track approval with those that 
underwent standard approval.  The Medicaid 
allowable cost (MAC) given to pharmacies that 
submit cost reimbursement claims for Medicaid 
clients was determined by adding the dispensing fee 
to the Medicaid ingredient cost (MIC).  The 
dispensing fee in fiscal year 2001-02 was $4.23 per 
claim for each drug dispensed. 
Thirty prescription drugs were selected for 
comparison, of which 15 were recalled and 15 were 
comparison drugs.  The recalled drugs were 
permanently withdrawn from the U.S. market after 
adverse health consequences were observed (Figure 
1).  Vioxx was not included in the analysis because it 
was a voluntary manufacturer recall, not an FDA 
mandated recall. 
Comparison drugs were obtained from 
Florida’s Preferred Drug List (PDL) that was 
instituted in 2001 as a cost containment mechanism 
for the rapidly rising costs of prescription 
medications for Medicaid patients.  The Florida 
Medicaid Preferred Drug List contains “prescription 
products selected by the Pharmaceutical and 
Therapeutics Committee as efficacious, safe and cost 
effective choices when prescribing for Medicaid 
Patients” (Agency for Health Care Administration, 
2004).  Comparison drugs were matched to the 
recalled drugs by therapeutic classification and drug 
function as shown in Figure 2. 
 
Results  
 Of the recalled drugs on the Medicaid 
preferred drug listing, 53% were drugs that were 
approved through the fast track mechanism, whereas 
47% of recalled drugs underwent standard approval.  
On the other hand, two out of three PDL comparison 
drugs that were not recalled were approved through 
the standard, albeit longer, review process.  Figure 3 
shows a graph and listing of recalled drugs and PDL 
comparison drugs by approval type.   
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Figure 1.  Drug Recalls 
Recall Date Brand Name Recall Reason Approval Date Post Market Time 
     
  9/15/1997 Redux® Abnormal Heart Valves   4/29/1996 1.5 years 
  2/27/1998 Seldane® Drug Interactions   5/08/1985 13 years 
  6/08/1998 Posicor® Sudden Deaths   6/20/1997 1 year 
  6/22/1998 Duract® Liver Failure   7/15/1997 1year 
  6/18/1999 Hismanal® Adverse Reaction Data 12/19/1998 6 months 
10/15/1999 Rotashield® Intussusception   8/31/1998 1 year 
11/01/1999 Raxar® Ventricular Arrhythmias 11/06/1997 2 years 
  3/21/2000 Rezulin® Liver Failure  1/29/1997 3 years 
  7/14/2000 Propulsid® Cardiac Arrhythmias  7/29/1993 7 years 
  7/26/2000 Norplant® System I Removal Problems 12/10/1990 9.5 years 
11/28/2000 Lotronex® Constipation Problems   2/09/2000 9 months 
  3/27/2001 Raplon® Bronchospasm    8/18/1999 1.5 years 
  8/08/2001 Baycol® Rhabdomyolysis    6/26/1997 4 years 
  3/01/2002 Versed® Potency, Crystallization   3/18/1997 5 years 
  2/28/2003 Trovan® Liver Toxicity 12/18/1997 5 years 
 
Figure 2.  Recalled Drugs and Comparison Drugs on the Medicaid Preferred Drug Listing 
Recalled Drug   Comparison Drug 
Brand (Generic) Name  Brand (Generic) Name   Function 
    
Baycol® (Cerivastatin)  Zocor® (Simvastatin) Cholesterol Lowering 
Duract® (Bromfenac)  Celebrex® (Celecoxib) Arthritis 
Hismanal® (Astemizole)  Zyrtec® (Cetirizine hydrochloride) Antihistamine 
Lotronex® (Alosetron)  Asacol® (Mesalamine) Bowel Disease (Crohn’s) 
Norplant® System I (Levonorgestrel) Norplant® System II (Levonorgestrel) Contraceptive 
Posicor® (Mibefradil)  Norvasc® (Amlodipine Besylate) High Blood Pressure 
Propulsid® (Cisapride)  Reglan® (Metoclopramide hydrochloride) Heartburn 
Raplon® (Rapacuronium bromide) Lioresal® (Baclofen)  Muscle Relaxant 
Raxar® (Grepafloxacin)  Cipro® (Ciprofloxacin hydrochloride) Antibiotic 
Redux® (Dexfenfluramine) Meridia® (Sibutramine monohydrate  
     hydrochloride) Weight Loss 
Rezulin® (Troglitazone)  Avandia® (Pioglitazone hydrochloride) Type 2 Diabetes 
Rotashield® (Rotavirus vaccine) Infanrix® (Rotavirus vaccine) DPT Vaccine 
Seldane® (Terfenadine)  Allegra® (Fexofenadine hydrocloride) Antihistamine 
Trovan® (Trovafloxacin) Tequin® (Gatifloxacin)  Antibiotic  
Versed® (Midazolam hydrochloride) Ativan® (Lorazepam)  Anxiety, Insomnia 
 [Insert Figure 3 about here] 
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47%
67%
33%
53%
Recalled Drugs                                PDL Comparison
Fast Track Standard
Figure 3.  Drug Approval Type for Recalled vs. 
PDL Comparison Drugs 
 
  
 
 
 
 
 
 
 
 
Recalled drugs comprised a total of 
$6,551.06 of Medicaid drug expenditures as 
measured by the Medicaid allowable cost 
(determined by the sum of Medicaid ingredient costs 
and dispensing fees of $4.23 per claim).  In contrast, 
the state spent $2,664,214.92 for the comparison 
drugs in fiscal year 2001-02.  Relative to the amount 
spent for comparison drugs, the amount spent on 
recalled prescription drugs was miniscule – 0.25% of 
comparison drugs (Figure 4 and Figure 5). 
  
Discussion 
The introduction and use of more expensive 
drugs in the same therapeutic category leads to 
increases in the average prescription drug price paid 
by consumers and institutional payers.  In Florida, 
utilization of new expensive drugs fueled the 
significant upsurge in Medicaid drug expenditures.  
Over the six-year period spanning fiscal years 1995-
96 through 2000-01, the average reimbursement for a 
Medicaid prescription rose by 84% from $34.40 to 
$63.23 (Agency for Health Care Administration, 
2001).   To stem the growth in prescription drug 
costs, a number of cost containment measures were 
instituted.  One of the pharmacy reforms enacted by 
the Florida legislature in 2001 was the development 
of the Medicaid preferred drug list.  This study found 
that Medicaid spending for recalled drugs was much 
lower than for comparison drugs on the preferred 
drug list, in part, because of fewer claims and 
associated dispensing fees.  By far the greatest 
number of claims among the recalled drugs was for 
the cholesterol-lowering medication, Baycol, a drug 
that was on the market for four years before removal 
in 2001. 
When looking at the Medicaid preferred 
drug list, it is clear that there are numerous drugs for 
each type of symptom and for many disease states.  A 
limitation of the study is that there is more than one 
drug for a given type of symptom or condition.  It is 
difficult to assign an exact substitute for every drug 
removed from the market.  This study’s selection of 
PDL drugs matched the removed drugs by 
therapeutic classification and drug function for 
comparisons of approval types. 
 In this analysis, a higher percentage of 
drugs approved via an accelerated process were 
recalled compared with those on the Florida 
Medicaid preferred drug list that received standard 
FDA approval.  Since 1992, speedier FDA reviews 
have been financed by industry-paid user fees 
authorized by Congress in the Prescription Drug User 
Fee Act (PDUFA).  Rather than the customary, multi 
year  review, waiting times for drug approval have 
 
 
Drugs Approval Type REMOVED 
Baycol® Standard Yes 
Duract® Standard Yes 
Redux® Fast track Yes 
Hismanal® Standard Yes 
Lotronex® Fast track Yes 
Norplant® System I Fast track Yes 
Posicor® Standard Yes 
Propulsid® Standard Yes 
Raplon® Fast track Yes 
Raxar® Standard Yes 
Rezulin® Fast track Yes 
Trovan® Fast track Yes 
Rotashield® Fast track Yes 
Seldane® Standard Yes 
Versed® Fast track Yes 
Allegra® Standard No 
Asacol® Fast track No 
Ativan® Standard No 
Avandia® Fast track No 
Celebrex® Fast track No 
Cipro® Fast track No 
Infanrix® Standard No 
Lioresal® Fast track No 
Meridia® Standard No 
Norplant® System II Standard No 
Norvasc® Standard No 
Reglan® Standard No 
Tequin® Standard No 
Zocor® Standard No 
Zyrtec® Standard No 
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Figure  4.  Medicaid Spending for Recalled Drugs (Fiscal Year 2001-02) 
RECALLED 
DRUGS 
# OF 
CLAIMS 
DISPENSING 
FEE($) 
 
COST 
 
QUANTITY 
Medicaid  
Ingredient Cost ($) 
Medicaid 
Allowable Cost ($) 
       
Baycol® 1,071 4,530.33 1.41 100   140.75        4,671.08 
Duract® 0 0 0.94 100 93.60 93.60 
Hismanal® 0 0 1.98 100   198.07    198.07  
Lotronex® 18      76.14 5.29 30   158.57    234.71  
Norplant® System I 0 0 420.51 1   420.51    420.51  
Posicor® 0 0 1.90 100   190.26    190.26  
Propulsid® 2        8.46 0.11 450 (mg/mL) 51.14 59.60 
Raplon® 0 0   25.14 10 (vials)   251.40    251.40  
Raxar® 0 0 2.14 60   128.48    128.48  
Redux® 0 0 0.92 30 27.66 27.66 
Rezulin® 0 0 1.55 100   154.90    154.90  
Rotashield® 0 0   16.59 2.5 (mL) 41.48  41.48 
Seldane® 0 0 1.13 30 33.83  33.83 
Trovan® 37     156.51 6.93 30   207.83    364.34  
Versed® 4      16.92 1.04 100 (mL)   103.86    120.78  
       
TOTAL 1,132 4,656.49 487.57 1,303.5       2,202.35      6,551.06 
 
Figure 5.  Medicaid Spending for PDL Comparison Drugs (Fiscal Year 2001-02) 
COMPARISON 
DRUGS 
# OF 
CLAIMS 
DISPENSING 
FEE ($) 
 
COST 
 
QUANTITY 
Medicaid  
Ingredient Cost ($) 
Medicaid 
Allowable Cost ($) 
       
Allegra® 967 4,090.41 1.21 100 121.00 4,211.41 
Asacol® 6,649 28,125.27 0.84 100   83.82 28,209.09 
Avandia® 31,685 134,027.55 4.39 100 439.41 134,466.96 
Celebrex® 237,181 1,003,275.63 2.46 100 246.49 1,003,522.12 
Cipro® 17,513 74,079.99 4.12 100 411.86 74,491.85 
Infanrix 0 0 19.29 5 (mL)   96.45 96.45 
Lioresal® 291 1,230.93 447.63 1 (kit) 447.63 1,678.56 
Lorazepam® 5,344 22,605.12 8.04 1 (vial)    8.04 22,613.16 
Meridia® 0 0 2.75 100 275.31 275.31 
Norplant® System II 2 8.46 434.42 1 (kit) 434.42 442.88 
Norvasc® 120,893 511,377.39 1.86 100 186.14 511,563.53 
Reglan® 22,790 96,401.70 0.54 100   54.45 96,456.15 
Tequinin® 1,504 6,361.92 8.05 30 241.46 6,603.38 
Zocor® 79,019 334,250.37 3.58 100 358.49 334,608.86 
Zyrtec® 106,148 449,006.04 1.81 100 180.57 49,186.61 
       
TOTAL 629,986 2,664,840.78 939.80 1,038 3,464.55 2,664,214.92 
 
been reduced, sometimes to less than one year.  
Recent studies have reported that the period for 
approval of priority drugs has decreased from 20 
months to 6 months (GAO, 2002 September; 
Carpenter, 2004; Olsen, 2004).   
Critics allege that the FDA has “systemic 
problems that contributed to the Vioxx catastrophe 
and to a long line of other drug safety failures in the 
past 10 years” (Fontanerosa, Drummond, & 
DeAngelis, 2004; Graham, 2004; Topol, 2004).  An 
early indication was an apparently higher recall rate 
after Congress enacted the PDUFA.  One analysis 
found that 5.34% of drugs approved between 1997 
and 2000 were removed from the market as 
compared to 1.56% between 1993 and 1996 (GAO, 
2002 September).   More recently, the number of 
drugs withdrawn from the market has declined from 
10 drugs removed between 1996 and 2001 to 3 
product withdrawals between 2001 and 2004 
(Kaufman & Masters, 2004).  Since 1997, only 16 
drugs have been recalled and withdrawn from the 
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market because of safety concerns (Associated Press, 
2004).   
The recent criticisms about the drug 
approval process prompted the FDA to propose 
measures to bolster the drug safety and approval 
process (Crawford FDA, 2004).  Among the 
recommendations were: (1) sponsoring an Institute of 
Medicine study of the drug safety system, (2) 
appointing a Director for the Office of Drug Safety 
who would oversee the post-marketing safety for all 
approved products, and (3) publishing risk 
management guidance.  It is anticipated that the 
FDA’s implementation of measures such as those 
above will improve the safety of new drugs and lead 
to better health outcomes for consumers. 
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